The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma

Leuk Lymphoma. 2017 Mar;58(3):736-739. doi: 10.1080/10428194.2016.1211279. Epub 2016 Aug 11.

Authors

Yusuke Kanemasa¹, Tatsu Shimoyama¹, Yuki Sasaki², Miho Tamura¹, Takeshi Sawada¹, Yasushi Omuro¹, Tsunekazu Hishima³, Yoshiharu Maeda¹

Affiliations

¹ a Department of Medical Oncology , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan.
² b Department of Clinical Research Support , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan.
³ c Department of Pathology , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo , Japan.

PMID: 27686739
DOI: 10.1080/10428194.2016.1211279

No abstract available

Publication types

Letter

MeSH terms

Age Factors
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / mortality*
Male
Prednisone / therapeutic use
Prognosis
Proportional Hazards Models
Rituximab
Treatment Outcome
Vincristine / therapeutic use

Substances

Antibodies, Monoclonal, Murine-Derived
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone